A CRISPR-Cas9-based therapy targeting the gene encoding transthyretin greatly reduced transthyretin levels in patients with ...

Eli Lilly LLY and AbbVie ABBV are large, well-established U.S. pharmaceutical companies, boasting several blockbuster drugs, ...

Odyssey Therapeutics, Inc., a clinical-stage biopharmaceutical company seeking to transform the standard of care for patients ...

Musunuru provided ESGCT delegates with promising news of a roadmap following the diagnosis and treatment of Baby KJ.

当叙事从理想回归现实，基因疗法这场始于狂喜、陷于困顿的宏大叙事，正迎来一个时代的转折点。巨头的集体退场，并非基因治疗梦想的终结，而是一场深刻的价值重构——行业正在抛弃对单一技术的盲目迷恋，转向一个更加多元、务实且以临床价值为最终导向的新范式。

AIRNA, a biotech company pioneering RNA editing therapeutics to transform the lives of patients with rare and common ...

从国外巨头到国内老牌企业的高额资金注入，折射出体内基因编辑的「单次给药、终身治愈」的精准治疗可行性，并有望覆盖从罕见病到常见病的全谱系疾病的潜力。接下来，小编盘点了今年来体内基因编辑领域代表性进展，以期为行业相关从业者提供参考。

In this article, we will be taking a look at the 10 Best Pharma Stocks to Buy According to Billionaires. Eli Lilly and Company is one of them. Eli Lilly and Company (NYSE:LLY) tops our list for being ...

Prime Medicine has had a lot to celebrate in recent months, from positive data to big-name investor interest, explaining a surge that has seen the prime editing therapy developer’s stock more than ...

In this Daily Rip Live clip, Shay Boloor tells Jordan why he’s excited about biotech and CRISPR names in his small-cap portfolio. 🧬 Shay owns Intellia ($NTLA), Beam ($BEAM), and Prime ($PRME), and ...

Deal structured in two payments: $19.1m upfront and $11.1m deferred. Integration expected to deliver $1.8m in annual cost and revenue synergies. The move strengthens Verve’s demand-side business and ...

Verve Group acquires Captify, strengthening its Demand Side business and securing one of the largest onsite search datasets outside Walled Gardens Acquisition of Captify will contribute revenues of ...